SCHEMBL4258294

SCHEMBL4258294

O=C(O)c1nn(Cl)c2ccccc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.52
CYP1A2 P05177 1/20 0.52
CYP3A4 P08684 1/20 0.52
CYP2D6 P10635 1/20 0.52
CYP2C9 P11712 1/20 0.52
PMP22 Q01453 1/20 0.52
HIF1A Q16665 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
ELANE P08246 7/20 0.49
SCN9A Q15858 1/20 0.42
F2 P00734 2/20 0.42
PLAU P00749 2/20 0.42
RORC P51449 1/20 0.42
MAPT P10636 2/20 0.41
PTGER4 P35408 1/20 0.41
ALDH1A1 P00352 3/20 0.41
HPGD P15428 1/20 0.41
PKM P14618 1/20 0.41
STAT1 P42224 2/20 0.40
KDM4E B2RXH2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28171820 0.85 ELANE (0.61) TSHRCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL1079201 0.80 ELANE (0.62) HIF1AELANEF2PLAUMAPT
SCHEMBL20674557 0.79 TSHR (0.47) TSHRCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL960949 0.79 ELANE (0.62) TSHRCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL30251861 0.78 KDM4E (0.62) TSHRCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL27758519 0.78 ELANE (0.57) TSHRCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL496589 0.78 KDM4E (0.62) TSHRCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL1967917 0.78 TSHR (0.46) TSHRCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL27937196 0.78 TSHR (0.46) TSHRCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL7421574 0.76 SCN9A (0.58) TSHRSCN9ARORCMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101239950-A 1-(substituted benzoyl)-indazole-3-carboxylate or amides compounds thereof, synthesis and application thereof UNIV PLA 2ND MILITARY MEDICAL (CN) 2008-08-13 CN claimed
CN-104812898-B The method for treating metabolic syndrome by adjusting the β of heat shock protein (HSP) 90 博格有限责任公司 2018-01-30 CN disclosed
CN-104640855-B Complement is by way of conditioning agent and application thereof 诺华股份有限公司 2017-08-29 CN disclosed
CN-104045625-A INDOLE AND INDAZOLE COMPOUNDS THAT ACTIVATE AMPK PFIZER 2014-09-17 CN disclosed
CN-103889976-A Indazole compounds, compositions and methods of use HOFFMANN LA ROCHE 2014-06-25 CN disclosed
CN-101239950-B 1-(substituted benzoyl)-indazole-3-carboxylate or amides compounds thereof, synthesis and application thereof UNIV PLA 2ND MILITARY MEDICAL 2011-01-19 CN disclosed
US-20090181968-A1 Novel 3-Bicyclocarbonylaminopyridine-2-Carboxamides or 3-Bicyclocarbonylaminopyrazine-2-Carboxamides ASTRAZENECA AB (SE) 2009-07-16 US disclosed
EP-1957478-A2 NEW COMPOUNDS AstraZeneca AB (SE) 2008-08-20 EP disclosed
CN-101239950-A 1-(substituted benzoyl)-indazole-3-carboxylate or amides compounds thereof, synthesis and application thereof UNIV PLA 2ND MILITARY MEDICAL (CN) 2008-08-13 CN disclosed
WO-2007061360-A2 NOVEL 3-BICYCLOCARBONYLAMINOPYRIDINE-2-CARBOXAMIDES OR 3-BICYCLOCARBONYLAMINOPYRAZINE-2-CARBOXAMIDES ASTRAZENECA AB (SE) 2007-05-31 WO disclosed
EP-1776338-A1 INDOLE, INDAZOLE OR INDOLINE DERIVATIVES F. Hoffmann-Roche AG (CH) 2007-04-25 EP disclosed
WO-2006013048-A1 INDOLE, INDAZOLE OR INDOLINE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2006-02-09 WO disclosed
EP-0558923-B1 Diazabicyclo derivatives as 5-HT3 antagonists NISSHIN FLOUR MILLING CO (JP) 2000-05-24 EP disclosed
US-5344831-A Antiemetics for treatment of nausea from chemotherapy NISSHIN FLOUR MILLING CO., LTD. (JP) 1994-09-06 US disclosed
US-5256656-A Antiserotonine agent NISSHIN FLOUR MILLING CO., LTD. (JP) 1993-10-26 US disclosed
EP-0558923-A1 Diazabicyclo derivatives as 5-HT3 antagonists NISSHIN FLOUR MILLING CO., LTD. (JP) 1993-09-08 EP disclosed
US-5187166-A Also useful as antipsychotic agents NISSHIN FLOUR MILLING CO., LTD. (JP) 1993-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181968-A1 Novel 3-Bicyclocarbonylaminopyridine-2-Carboxamides or 3-Bicyclocarbonylaminopyrazine-2-Carboxamides H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNA2, CNR2 TSHR 1608/4885CYP1A2 49/4885CYP3A4 465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.